PTPN22

Across TCGA pan-cancer cohorts, PTPN22 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PTPN22’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PTPN22 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PTPN22 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

LSCC, PDAC, and LUAD are the cancer types where PTPN22 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPN22 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.177	.004	4	view →
PDAC	Female	All	+0.830	.012	3	view →
LUAD	Female	III,IV	+0.315	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PTPN22–LSCC

Open the LSCC breakdown →